Hadi, Arina Rizka (2017) Perbandingan Efektivitas Terapi Hepatitis C Berbasis Peginterferon Alfa 2a Dan Efek Samping Hematologi Pada Pasien Di Rsud Dr. Saiful Anwar. Sarjana thesis, Universitas Brawijaya.
Abstract
VHC penyebab 70% semua penyakit hepatitis kronik. Pengobatan berbasis interferon memiliki efek samping tinggi, termasuk pada hematologi. Fokus penelitian pada perbandingan efektivitas terapi hepatitis C berbasis PEG-IFN α2a dan efek samping hematologi. Data yang digunakan, data rekam medis pasien hepatitis C. Pengambilan sampel menggunakan consecutive sampling sesuai inklusi dan eksklusi berjumlah 66 pasien. Uji komparatif penelitian ini menggunakan uji One-Way ANOVA, Kruskal Wallis, dan t tidak berpasangan. Uji Kruskal Wallis RNA VHC M1-M24 (p = 0,876; 0,922; 0,340) dosis Pegasys (90- 180 μg) dan RBV (400-800 mg) menurunkan nilai RNA VHC hingga tidak terdeteksi. Uji One-Way ANOVA nilai hemoglobin M1-M48 p < 0,05 (p = 0,000; 0,000; 0,002; 0,003; 0,000) menghasilkan perbedaan penurunan nilai hemoglobin, Pegasys (90 μg dan 180 μg) menurunankan nilai hemoglobin dan RBV 400 mg menghasilkan nilai hemoglobin lebih kecil. Uji One Way ANOVA trombosit M1,M24-36 p < 0,05 (p = 0,000; 0,000; 0,007) dan Kruskal Wallis trombosit M12 p < 0,05 (p = 0,000) menghasilkan perbedaan penurunan nilai trombosit, Pegasys 180 μg/RBV 400 mg nilai tombosit normal. Uji One Way ANOVA nilai leukosit M48 (p = 0,031) menghasilkan perbedaan penurunan nilai leukosit, Pegasys 90 μg nilai leukosit stabil. Uji t tidak berpasangan minggu ke-48 p < 0,05 (p = 0,040), Pegasys 90 μg menghasilkan nilai neutrofil lebih rendah daripada. Kesimpulan: berbagai dosis terapi PEG-Interferon kombinasi RBV dapat menurunkan nilai RNA VHC hingga tidak terdeteksi dan memiliki perbedaan nilai hemoglobin, tombosit, leukosit, atau neutrofil.
English Abstract
HCV is the cause of 70% of chronic hepatitis. Interferon-based treatment has high frequency of side effects, including hematologic. This research focused on comparison of hepatitis C therapy effectiveness based on PEG-IFN α2a and hematologic side effects. This research used medical record data. Data sampling method was consecutive sampling up to 66 patients. Comparative test in this study used One-Way ANOVA, Kruskal Wallis, and independent t test. Kruskal Wallis test on RNA VHC M1-M24 was (p = 0,876; 0,922; 0,340) Pegasys (90-180 μg) and RBV (400-800 mg) lowered VHC RNA values until undetected. One-Way ANOVA test on hemoglobin M1-48 was p < 0,05 (p = 0.000, 0,000, 0.002, 0.003, 0.000) resulted in differences of hemoglobin values, Pegasys (90 μg and 180 μg) lowered hemoglobin values and RBV 400 mg had smaller hemoglobin values. One-Way ANOVA test on platelets M1, M24-36 was p < 0.05 (p = 0.000; 0.000; 0.007) and Kruskal Wallis test M12 was p < 0.05 (p = 0.000) resulted in differences of platelet values, Pegasys 180 μg/RBV 400 mg platelets values in normal limits. One-Way ANOVA test on leukocyte M48 was p > 0.05 (p = 0.031) resulted in differences of leukocyte values, Pegasys 90 μg leukocytes values were stable. Independent t test on neutrophil was p < 0.05 (p = 0.040) Pegasys 90 μg had low neutrophil values. In coclusion, various doses PEG-Interferon therapy in combinations with RBV can decrease the value of HCV RNA and have different hematological values (hemoglobin, platelet, leukocyte, or neutrophil).
| Item Type: | Thesis (Sarjana) |
|---|---|
| Identification Number: | SKR/FK/2017/473/051800392 |
| Uncontrolled Keywords: | Hepatitis C, PEG-Interferon, Ribavirin, RNA VHC, efek samping hematologi, Hepatitis C, PEG-Interferon, Ribavirin, HVC RNA, hematologic side effects |
| Subjects: | 600 Technology (Applied sciences) > 616 Diseases > 616.3 Diseases of digestive system > 616.36 Diseases of biliary tract and liver > 616.362 Diseases of liver /Liver--Diseases > 616.362 06 Liver--Diseases--Treatment |
| Divisions: | Fakultas Kedokteran > Farmasi |
| Depositing User: | Nur Cholis |
| Date Deposited: | 15 Jan 2018 08:32 |
| Last Modified: | 24 Oct 2021 05:41 |
| URI: | http://repository.ub.ac.id/id/eprint/8055 |
Preview |
Text
ABSTRAK.pdf Download (116kB) | Preview |
Preview |
Text
BAB 1.pdf Download (202kB) | Preview |
Preview |
Text
BAB 2.pdf Download (328kB) | Preview |
Preview |
Text
BAB 3.pdf Download (267kB) | Preview |
Preview |
Text
BAB 4.pdf Download (270kB) | Preview |
Preview |
Text
BAB 5.pdf Download (492kB) | Preview |
Preview |
Text
BAB 6.pdf Download (276kB) | Preview |
Preview |
Text
BAB 7.pdf Download (7kB) | Preview |
Preview |
Text
BAGIAN DEPAN.pdf Download (686kB) | Preview |
Preview |
Text
COVER-DAFTAR ISI.pdf Download (324kB) | Preview |
Preview |
Text
DAFTAR PUSTAKA.pdf Download (335kB) | Preview |
Preview |
Text
Lampiran.pdf Download (2MB) | Preview |
Preview |
Text
Lembar pengesahan.pdf Download (217kB) | Preview |
Actions (login required)
 |
View Item |